Neither atezolizumab alone or with cobimetinib improved overall survival, objective responses or progression-free survival in patients with metastatic colon cancer compared to the standard approach of using regorafenib, according to data presented at the ESMO World Congress on Gastrointestinal Cancer 2018 on June 20 to June 23 in Barcelona, Spain, and detailed in Medscape.
Here are three things to know:
1. The IMblaze370 phase 3 trial included more than 360 metastatic CRC patients for whom at least two prior chemotherapy regimens had failed.
2. The majority of participants — 90 percent — had tumors characterized by microsatellite stability; tumors with microsatellite instability have been shown to respond to immunotherapy.
3. There was no significant difference in progression-free survival between the treatments.
More articles on gastroenterology:
$5k colonoscopy? Contract dispute in Mississippi could mean patients foot the bill
Pentax Medical posts lecture series on endoscopic infection control — 6 insights